A Detroit Medical Center hospital has begun treating patients with the first gene therapy for beta-thalassemia, a rare blood ...

Life expectancy for people with sickle cell in the U.S. has increased to about 50 years, but some people with the disease still face stigma and other barriers in health care ...

He also believes there’s still too few of the therapies on the market to draw any sweeping conclusions on reasons for their ...

Screenings can be conducted before or during pregnancy and couples may be referred to the programme during obstetric visits ...

For those with $200 to spare that isn't being saved for emergencies, let's consider two healthcare stocks within that budget ...

Bristol Myers Squibb Company BMY is experiencing a good run of late after touching a 52-week low of $39.35 on July 5. This ...

CRISPR Therapeutics' first therapy is called Casgevy. It treats sickle cell disease (SCD) and beta thalassemia, both rare inherited illnesses that affect the function of a person's red blood cells. It ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” second quarter 2024 investor letter. A ...

The future of CRISPR involves clinical trials focused on treatment for blood diseases and cancers, cardiovascular disease, ...

We recently compiled a list of the 12 Best Biotech Stocks To Invest In According To Hedge Funds. In this article, we are ...

Global Blood Transfusion Diagnostics Market is valued at approximately USD 4.6 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.9% over the forecast period ...